Tumour-induced expansion of regulatory T (TReg) cells is an obstacle to successful cancer immunotherapy. The potential benefit of T Reg-cell depletion through the interleukin-2 receptor is lost by the concurrent elimination of activated effector lymphocytes and possibly by the de novo induction of TReg-cell replenishment. In theory, the functional inactivation of TReg cells will maintain them at high numbers in tumours and avoid their replenishment from the peripheral lymphocyte pool, which has the capacity to further suppress the effector lymphocyte anti-tumour response.
ASJC Scopus subject areas
- Cancer Research